OPB-51602

N/A

Report date: 2022/07/19 16:22:54
NME

Base Information

Drug NameOPB-51602
Drug Alias NameOPB-51602
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSignal transducer and activator of transcription 3 inhibitors
TargetsSignal transducer and activator of transcription 3
Therapy Area/IndicationsSolid tumoursMultiple MyelomaNasopharyngeal Carcinoma +[8] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesSingaporeJapan
CombinationsNo
Global Highest StatusDiscontinued (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesOtsuka Holdings Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesOtsuka Pharmaceutical Development & Commercialization IncOtsuka Pharmaceutical Co LtdOtsuka Beijing Research Institute
Active IndicationsN/A
Inactive IndicationsSolid tumoursMultiple MyelomaNasopharyngeal Carcinoma +[8] 

Other Information

ATC CodeN/A
Related LinksN/A